Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapyChunshui Liu(First Hospital of Jilin University), Sujun Gao(Jilin University)Oncology ReportsJune 11, 201910.3892/or.2019.7194Cited by 10SaveCiteExport RISWatch citationsRelated PapersGolidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study|The Lancet Oncology|2023|55